INBX
Inhibrx Biosciences, Inc.81.57
+5.36+7.03%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.19BP/E (TTM)
-Basic EPS (TTM)
-11.96Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Ozekibart succeeds in chondrosarcoma trial
Inhibrx announced positive topline results from the ChonDRAgon study on October 23, 2025, where ozekibart met its primary endpoint, slashing progression risk by 52% (HR 0.479) in advanced chondrosarcoma patients versus placebo. Disease control doubled to 54%, with benefits in pain and function. Interim data from colorectal cancer and Ewing sarcoma cohorts showed 23% and 64% response rates, respectively, in tough cases. BLA filing targets Q2 2026. Topline data may evolve.
8-K
Q2 loss, trials advance
Inhibrx Biosciences reported Q2 2025 financials, posting a $28.7 million net loss amid reduced R&D and G&A expenses following the prior year's INBRX-101 sale to Sanofi. Cash reserves stood at $186.6 million as of June 30, down from $216.5 million in Q1. Key trials advanced: ozekibart's Phase 2 in chondrosarcoma fully enrolled, with PFS data due late October 2025. INBRX-106 combo data expected Q4. Milestones loom large.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
FBLG
FibroBiologics, Inc.
0.24-0.02
FBRX
Forte Biosciences, Inc.
23.27+1.31
IBIO
iBio, Inc.
2.06+0.23
IBRX
ImmunityBio, Inc.
2.16-0.06
INAB
IN8bio, Inc.
1.50-0.10
INMB
INmune Bio Inc.
1.89-0.02
IVBXF
Innovent Biologics Inc.
10.55+0.00
NBTX
Nanobiotix S.A.
22.32+0.18
VINC
Vincerx Pharma, Inc.
0.01+0.00